Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
AstraZeneca
Harvard Business School
Dow
Boehringer Ingelheim

Last Updated: November 29, 2022

Investigational Drug Information for Odalasvir


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Odalasvir?

Odalasvir is an investigational drug.

There have been 13 clinical trials for Odalasvir. The most recent clinical trial was a Phase 2 trial, which was initiated on April 10th 2017.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis C, Chronic. The leading clinical trial sponsors are Janssen Research & Development, LLC, Alios Biopharma Inc., and Janssen Pharmaceutical K.K.

There are fourteen US patents protecting this investigational drug and one hundred and forty-four international patents.

Recent Clinical Trials for Odalasvir
TitleSponsorPhase
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic FunctionJanssen Research & Development, LLCPhase 1
A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy ParticipantsJanssen Research & Development, LLCPhase 1
A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) InfectionJanssen Research & Development, LLCPhase 3

See all Odalasvir clinical trials

Clinical Trial Summary for Odalasvir

Top disease conditions for Odalasvir
Top clinical trial sponsors for Odalasvir

See all Odalasvir clinical trials

US Patents for Odalasvir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Odalasvir See Plans and Pricing Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero- heteraphanes and metallocenes useful for treating HCV infections Achillion Pharmaceuticals, Inc. (New Haven, CT) See Plans and Pricing
Odalasvir See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Odalasvir See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
AstraZeneca
Harvard Business School
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.